389 related articles for article (PubMed ID: 16214136)
21. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
Huang WC; Westlake AC; Maréchal JD; Joyce MG; Moody PC; Roberts GC
J Mol Biol; 2007 Oct; 373(3):633-51. PubMed ID: 17868686
[TBL] [Abstract][Full Text] [Related]
22. A highly active single-mutation variant of P450BM3 (CYP102A1).
Whitehouse CJ; Bell SG; Yang W; Yorke JA; Blanford CF; Strong AJ; Morse EJ; Bartlam M; Rao Z; Wong LL
Chembiochem; 2009 Jul; 10(10):1654-6. PubMed ID: 19492389
[TBL] [Abstract][Full Text] [Related]
23. Probing the structure of the linker connecting the reductase and heme domains of cytochrome P450BM-3 using site-directed mutagenesis.
Govindaraj S; Poulos TL
Protein Sci; 1996 Jul; 5(7):1389-93. PubMed ID: 8819171
[TBL] [Abstract][Full Text] [Related]
24. Cyclopropyl fatty acids implicate a radical but not a cation as an intermediate in P450BM3-catalysed hydroxylations.
Cryle MJ; Stuthe JM; Ortiz de Montellano PR; De Voss JJ
Chem Commun (Camb); 2004 Mar; (5):512-3. PubMed ID: 14973583
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of alkoxyresorufins as fluorescent substrates for cytochrome P450 BM3 and site-directed mutants.
Lussenburg BM; Babel LC; Vermeulen NP; Commandeur JN
Anal Biochem; 2005 Jun; 341(1):148-55. PubMed ID: 15866539
[TBL] [Abstract][Full Text] [Related]
26. Flavocytochrome P450 BM3 and the origin of CYP102 fusion species.
Girvan HM; Waltham TN; Neeli R; Collins HF; McLean KJ; Scrutton NS; Leys D; Munro AW
Biochem Soc Trans; 2006 Dec; 34(Pt 6):1173-7. PubMed ID: 17073779
[TBL] [Abstract][Full Text] [Related]
27. A single mutation in cytochrome P450 BM3 induces the conformational rearrangement seen upon substrate binding in the wild-type enzyme.
Joyce MG; Girvan HM; Munro AW; Leys D
J Biol Chem; 2004 May; 279(22):23287-93. PubMed ID: 15020590
[TBL] [Abstract][Full Text] [Related]
28. Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis.
van Vugt-Lussenburg BM; Stjernschantz E; Lastdrager J; Oostenbrink C; Vermeulen NP; Commandeur JN
J Med Chem; 2007 Feb; 50(3):455-61. PubMed ID: 17266197
[TBL] [Abstract][Full Text] [Related]
29. Improving catalytic properties of P450 BM3 haem domain electrodes by molecular Lego.
Fantuzzi A; Meharenna YT; Briscoe PB; Sassone C; Borgia B; Gilardi G
Chem Commun (Camb); 2006 Mar; (12):1289-91. PubMed ID: 16538250
[TBL] [Abstract][Full Text] [Related]
30. Control of electron transfer in neuronal NO synthase.
Daff S; Noble MA; Craig DH; Rivers SL; Chapman SK; Munro AW; Fujiwara S; Rozhkova E; Sagami I; Shimizu T
Biochem Soc Trans; 2001 May; 29(Pt 2):147-52. PubMed ID: 11356143
[TBL] [Abstract][Full Text] [Related]
31. Structural and spectroscopic characterization of P450 BM3 mutants with unprecedented P450 heme iron ligand sets. New heme ligation states influence conformational equilibria in P450 BM3.
Girvan HM; Seward HE; Toogood HS; Cheesman MR; Leys D; Munro AW
J Biol Chem; 2007 Jan; 282(1):564-72. PubMed ID: 17077084
[TBL] [Abstract][Full Text] [Related]
32. Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites.
Damsten MC; van Vugt-Lussenburg BM; Zeldenthuis T; de Vlieger JS; Commandeur JN; Vermeulen NP
Chem Biol Interact; 2008 Jan; 171(1):96-107. PubMed ID: 17996858
[TBL] [Abstract][Full Text] [Related]
33. Protein engineering of the cytochrome P450 monooxygenase from Bacillus megaterium.
Urlacher VB; Schmid RD
Methods Enzymol; 2004; 388():208-24. PubMed ID: 15289074
[No Abstract] [Full Text] [Related]
34. Subzero-temperature stabilization and spectroscopic characterization of homogeneous oxyferrous complexes of the cytochrome P450 BM3 (CYP102) oxygenase domain and holoenzyme.
Perera R; Sono M; Raner GM; Dawson JH
Biochem Biophys Res Commun; 2005 Dec; 338(1):365-71. PubMed ID: 16197919
[TBL] [Abstract][Full Text] [Related]
35. Flavocytochrome P450 BM3 substrate selectivity and electron transfer in a model cytochrome P450.
Munro AW; Noble MA; Ost TW; Green AJ; McLean KJ; Robledo L; Miles CS; Murdoch J; Chapman SK
Subcell Biochem; 2000; 35():297-315. PubMed ID: 11192726
[No Abstract] [Full Text] [Related]
36. Structure, electronic properties and catalytic behaviour of an activity-enhancing CYP102A1 (P450(BM3)) variant.
Whitehouse CJ; Yang W; Yorke JA; Tufton HG; Ogilvie LC; Bell SG; Zhou W; Bartlam M; Rao Z; Wong LL
Dalton Trans; 2011 Oct; 40(40):10383-96. PubMed ID: 21603690
[TBL] [Abstract][Full Text] [Related]
37. Interaction of nitric oxide with cytochrome P450 BM3.
Quaroni LG; Seward HE; McLean KJ; Girvan HM; Ost TW; Noble MA; Kelly SM; Price NC; Cheesman MR; Smith WE; Munro AW
Biochemistry; 2004 Dec; 43(51):16416-31. PubMed ID: 15610036
[TBL] [Abstract][Full Text] [Related]
38. Flavocytochrome P450 BM3: an update on structure and mechanism of a biotechnologically important enzyme.
Warman AJ; Roitel O; Neeli R; Girvan HM; Seward HE; Murray SA; McLean KJ; Joyce MG; Toogood H; Holt RA; Leys D; Scrutton NS; Munro AW
Biochem Soc Trans; 2005 Aug; 33(Pt 4):747-53. PubMed ID: 16042591
[TBL] [Abstract][Full Text] [Related]
39. P450BM-3: absolute configuration of the primary metabolites of palmitic acid.
Truan G; Komandla MR; Falck JR; Peterson JA
Arch Biochem Biophys; 1999 Jun; 366(2):192-8. PubMed ID: 10356283
[TBL] [Abstract][Full Text] [Related]
40. Effect of the Insertion of a Glycine Residue into the Loop Spanning Residues 536-541 on the Semiquinone State and Redox Properties of the Flavin Mononucleotide-Binding Domain of Flavocytochrome P450BM-3 from Bacillus megaterium.
Chen HC; Swenson RP
Biochemistry; 2008 Dec; 47(52):13788-99. PubMed ID: 19055322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
